This is an exploratory study which will evaluate Galantamine in cognitive deficits (learning) in patients with schizophrenia. The trial will last for 8 weeks. Efficacy and safety will be studied. The patients must be on a stable dose of an antipsychotic and smoke cigarettes.

Condition	Treatment or Intervention	Phase
Schizophrenia	Drug: Galantamine ER	Phase II

Further Study Details: 

Primary Outcomes: Computerized Cognitve test battery
Expected Total Enrollment:  100

Ages Eligible for Study:  18 Years   -   55 Years,  Genders Eligible for Study:  Both

Criteria

• Patient must be on a stable atypical antipsychotic for at least 30 days
• Women of child bearing potential must use approved method of birth control
• Patients must smoke at least 5 cigarettes per day
• Patient cannot have major medical problems

Canada, Alberta
      Psychopharmcology Research Unit, Edmonton,  Alberta,  T6G 2B7,  Canada; Recruiting
      Foothills Medical Center, Calgary,  Alberta,  T2N T9,  Canada; Recruiting
Canada, Manitoba
      Health Sciences Center, Winnipeg,  Manitoba,  R3E 3N4,  Canada; Recruiting
Canada, Ontario
      Providence Continuing Care Center, Kingston,  Ontario,  K7L 4X3,  Canada; Recruiting
      Royale Ottawa Hospital, Ottawa,  Ontario,  K17 7K4,  Canada; Recruiting

Study ID Numbers:  GAL-SCH-201
Record last reviewed:  October 2004
Last Updated:  October 28, 2004
Record first received:  February 11, 2004
ClinicalTrials.gov Identifier:  NCT00077727
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08